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Background: Inhaled corticosteroids (ICS) are widely used in the treatment of chronic 
obstructive pulmonary disease (COPD), but recent studies have raised doubts whether all 
COPD patients will benefit from ICS. This study evaluates in a real-life setting the effects of 
ICS withdrawal in patients with COPD.
Methods: The study was a prospective intervention study following patients with COPD for 
6 months after abrupt withdrawal of ICS. FEV1 (L), blood eosinophilic count (x10E9/L) and 
number of exacerbations were measured at baseline, 1, 3 and 6 months after ICS withdrawal.
Results: Ninety-six patients (56 females (57.4%), mean age 70 years (51–94 years)) with 
COPD were included in the study. Eleven patients were excluded during the study period (7 
patients died, 4 patients withdrew their consent during the study period). During the 6 
months, 51 patients (60%) had resumed treatment with ICS, of whom 34 patients (68%) 
experienced an exacerbation during follow-up. No significant decline in FEV1 was seen in 
this group between baseline and after 6 months (ΔFEV1 0.07 L, p = 0.09). In the remaining 
34 patients (40%) without ICS after 6 months of follow-up, 15 patients (44.1%) experienced 
an exacerbation. No significant decline was seen in FEV1 at baseline and after 6 months 
(ΔFEV1 0.04 L, p = 0.28). There were no statistically significant differences between the two 
groups in age (70.5 vs 69.6 years, p = 0.53), nor between FEV1 at baseline (0.96 L vs 1.00 L, 
p = 0.63) or eosinophilic count (0.25 x10E9/L vs 0.17 x10E9/L, p = 0.07).
Conclusion: Abrupt withdrawal of ICS was possible in some patients. However, more than 
half of the patients resumed ICS during follow-up. Based on results from our study we were 
not able to foresee – from neither history of exacerbations nor eosinophilic count – whom 
will be able to manage without ICS and who will resume treatment with ICS.
Keywords: COPD, inhaled corticosteroids, withdrawal, real-life setting
Introduction
Chronic obstructive pulmonary disease (COPD) is a progressive chronic disease in 
which airway inflammation plays an important role in the pathogenesis of the 
disease. Frequent symptoms include dyspnea, chronic cough, and sputum 
production.1,2 Inhalation treatment of patients with COPD has been shown to 
reduce symptoms and exacerbations, and consists primarily of 3 classes of medica-
tions, beta-2 agonists, antimuscarinic drugs, and inhaled corticosteroids, either 
alone or in combinations.1
However, as COPD has different phenotypes, eg, frequent exacerbators, high 
eosinophilic count, and coexistence with asthma,3,4 not all patients should be 
treated the same.5 Especially the use of inhaled corticosteroids (ICS) is much 
debated because of several potential adverse effects, such as increased risk of 
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pneumonia, poor diabetes control, oral candidiasis, 
increased risk of osteoporosis and benign fractures and 
cataract.6–13 In 2016, results from the FLAME study 
showed that combination treatment with long-acting beta- 
2 agonists and long-acting antimuscarinic drugs (LABA/ 
LAMA) was superior to the combination LABA/ICS in 
preventing COPD exacerbations in patients with a history 
of exacerbations during the previous year.14 According to 
current GOLD 2020 report, ICS should only be considered 
in patients with ≥2 exacerbations/year, blood eosinophils 
>300 cells/µL and/or concomitant asthma, and should not 
be given to patients with repeated pneumonia and blood 
eosinophils <100 cells/µL.1
However, for several reasons many patients with 
COPD without the abovementioned criteria are treated 
with ICS anyway.11,15 Based on GOLD recommendations 
for withdrawal of ICS in patients with COPD not meeting 
the criteria, several studies have evaluated the effect of 
withdrawal from ICS in patients with COPD and found no 
differences in number of exacerbations or changes in lung 
function compared to patients continuing ICS.16–19 
Contrary to most study populations, many of the COPD 
patients in real life have been treated with ICS for a long 
period with an expectation of beneficial effect and thus it 
may be difficult to stop treatment from one day to another. 
We hypothesized that ICS withdrawal would be possible 
yet problematic in patients with COPD. Therefore, in this 
study, we aimed to follow patients with COPD for 6 
months after abrupt withdrawal of ICS with the purpose 
of evaluating the consequences of withdrawal and the 
patients’ ability to avoid ICS.
Methods
Settings and Study Population
The current study was conducted using data from the 
pulmonary outpatient clinic at Little Belt Hospital, 
Denmark. The study was a prospective intervention study 
following consecutive patients with COPD for 6 months 
after abrupt withdrawal of ICS. Baseline data were col-
lected from January to November 2017 and follow-up data 
were conducted in the following 6 months from study 
entry. Subjects were followed for 6 months from study 
entry or until death or lost to follow-up, whichever came 
first.
To be included in the study, patients should be diag-
nosed with COPD and treated with one of the following 
types of ICS for more than 6 months: fluticasone, 
budesonide or beclomethasone. Daily dose for all 
patients was calculated and converted to match the 
dose of budesonide. Mean daily dose was equivalent to 
740 µg of budesonide. Additionally, all patients should 
be treated with LABA and LAMA prior to inclusion as 
well as throughout the entire study period. When ICS 
was withdrawn, patients continued using their LABA/ 
LAMA inhalator device. If patients were treated with a 
combined inhalator containing ICS, they were changed 
to a similar device without ICS to ensure the same 
inhalator technique.
Only patients who had already been diagnosed with 
COPD and followed for several years in the out-patient 
clinic by pulmonologists were included. Furthermore, 
patients should be able to read and understand the infor-
mation written in Danish. Key exclusion criteria included 
a known history of asthma.
At study entry, the following data were collected: 
smoking status including smoking history (pack-years), 
history of exacerbations during a 12-month period prior 
to inclusion and number of comorbidities.
Patients were examined by a doctor at study entry and 
at 6 months follow-up. One month after study entry the 
patients were telephoned by a nurse and at 3 months 
follow-up patients were seen by a nurse. If needed, the 
patients could at any time ask to see a doctor or a nurse. At 
study entry and at 3 months follow-up, patients’ eosino-
philic count was measured, whereas FEV1 was measured 
at study entry, at 3 months follow-up and at end of the 
study. At 1, 3 and 6 months, self-reported use of antibio-
tics and/or prednisolone were measured as exacerbations. 
At the same timepoints patients were asked whether they 
had resumed ICS (Figure 1).
Patients were allowed to resume ICS if needed and 
should not necessarily consult a doctor à priori.
The study population consisted of patients with COPD 
who consecutively gave informed consent for follow-up 
monitoring until May 2018.
COPD and COPD Exacerbations
The diagnosis of COPD was confirmed by a doctor and a 
pre-bronchodilator test with the forced expiratory volume 
in 1 sec (FEV1)/forced vital capacity (FVC) < 0.7.
COPD exacerbations were defined as an acute episode 
of worsening of COPD symptoms requiring a course of 
systemic corticosteroids and/or antibiotics reported by the 
patients.
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Endpoints
The primary endpoint in this study was to demonstrate 
whether patients could manage to stay off ICS after abrupt 
withdrawal measured by changes in FEV1 and number of 
exacerbations during a 6-months follow-up period from 
abrupt withdrawal.
Key secondary endpoint was to see if it could be 
possible from the data to foresee which patients could 
not do without ICS treatment.
Statistical Analysis
Mean lung function and mean blood eosinophilic count at 
baseline and during follow-up was calculated using data 
from each individual included in the study. Potential dif-
ferences in lung function, number of exacerbations and 
eosinophilic count were calculated using the Data 
Analysis program from the Microsoft Office Excel version 
2020. For all analyses, a p-value < 0.05 was defined to be 
significant.
Results
Characteristics of the Study Population
Overall, 96 patients (56 females, 58.3%), mean age 70 
years (51–94 years) with COPD were included in the 
study. During the study period, 11 patients were excluded 
(7 patients died, 4 patients withdrew their consent during 
the study period), leaving 85 patients for complete 
analysis.
Lung function at baseline was 0.97 L (40.55% pre-
dicted) with the majority of patients (65%) classified to 
be GOLD D. Most patients reported MRC 2–4. There 
were no never smokers, 77.1% were former smokers 
while 22.9% were current smokers. Mean overall pack-
years were 45.6.
In total, 45 patients (52,9%) had had one or more 
exacerbations in the past 12 months prior to inclusion. 
Overall blood eosinophilic count at baseline was 0.22 x 
10E9/L. Patients with a history of exacerbations prior to 
inclusion had a non-significant higher concentration at 
baseline compared to patients with no history of exacer-
bations (0.24x10E9/L vs 0.19x10E9/L, p 0.29). Baseline 
characteristics are shown in Table 1.
Primary Endpoints
Characteristics of Patients Resuming ICS During 
Follow-Up
During the 6 months of follow-up, 51 patients (60%) had 
resumed treatment with ICS. Of these, 28 patients (54.9%) 
had resumed ICS treatment after 1 month, another 16 
patients (31.4%) after 3 months and further 7 patients 
(13.7%) after 6 months. Their mean daily dose of ICS 
prior to inclusion was 748 µg.
Of those resuming ICS, 34 patients (68%) experi-
enced one or more exacerbations during follow-up, of 
whom 20 patients (58.8%) had been treated with anti-
biotics during the first month from withdrawal (Table 2). 


























Figure 1 Study design. 
Abbreviations: ICS, inhaled corticosteroids; FEV1, forced expiratory volume in 1st second.
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Among the 34 patients experiencing an exacerbation 
during follow-up, 19 patients (56%) had had one or 
more exacerbations prior to inclusion, whereas 8 (50%) 
of the 17 patients not having an exacerbation during 
follow-up had had one or more exacerbations prior to 
inclusion (Table 3 and Figure 2). In Suppl. figure 1, 
we have shown the proportion of patients with 2 or 
more exacerbations at baseline according to the two 
groups (+/- ICS). No difference was seen between 
patients resuming ICS and those who managed to stay 
without.
A decline in FEV1 was seen between baseline and 
after 6 months (ΔFEV1 0.07 L), however, the decline 
was not statistically significant (p = 0.09) (Table 4). The 
biggest decline in FEV1 from baseline to 6 months post 
inclusion was seen for those who resumed ICS after 3 
months (ΔFEV1 = 0.11 litres) whereas no change in 
FEV1 was seen for those who resumed ICS between 4 
and 6 months after withdrawal (ΔFEV1 = −0.01 litres) 
(Suppl. Table 1).
No statistically significant difference in eosinophilic 
count at baseline was seen between patients with and 
without exacerbations during follow-up (0.24 x10E9/L vs 
0.28 x10E9/L, p > 0.5) (Table 5).
Characteristics of Patients Not Resuming ICS During 
Follow-Up
Thirty-four patients (40%) remained without ICS during 
follow-up. Of these, 15 patients (44.1%) experienced an 
exacerbation during follow-up and of these, 6 patients 
(40%) received antibiotics during the first month from 
withdrawal (Table 2). Mean daily dose of ICS prior to 
inclusion was 708.8 µg.
Eleven (73.3%) of the 15 patients experiencing one or 
more exacerbations during follow-up had had exacerba-
tions prior to inclusion, whereas only 7 (36.8%) of the 19 
patients not having exacerbations during follow-up had 
had exacerbations prior to inclusion (Table 3 and 
Figure 2).
No statistically significant difference was seen 
between FEV1 at baseline and after 6 months (ΔFEV1 
0.04 L, p = 0.28) as well as no statistically significant 
difference in eosinophilic count at baseline was seen 
between patients with and without exacerbations during 
follow-up (0.15 x10E9/L vs 0.18 x10E9/L, p > 0.5) 
(Tables 4 and 5).
When comparing the patients resuming ICS during 
follow-up to patients not resuming ICS we found no sta-
tistically significant differences in age (70.5 vs 69.6 years) 
or sex distribution (40% vs 47.1% males, p > 0.5), nor 
between BMI, GOLD classification or reported MRC. 
FEV1 at baseline (0.96 L vs 1.00 L, p = 0.63) and eosi-
nophilic count (0.25 x10E9/L vs 0.17 x10E9/L, p = 0.07) 
were not statistically different either between the two 
groups.
Baseline characteristics according to ICS during fol-
low-up are shown in Table 3.
Table 1 Baseline Characteristics
Total Population Completing the 
Study  
(n = 85)
Gender (%M) 36 (42.3)
BMI, mean (range) 25 (12–44)













Former smokers no. (%) 74 (77.1)
Current smokers no. (%) 22 (22.9)
Pack years, mean (±) 45.55 (8–90)
Daily dose of ICS, mean (µg) 740
Lung function
FEV1 0.97 (0.25–2.30)
FEV1% pred. 40.55 (12–93)
No. of patients with exacerbations prior 
to inclusion (%)
45 (52.9)
Blood eosinophil conc. 0.22 (0–1.22)
Exa. prior to inclusion 0.24 (0–1.22)
No exa. prior to inclusion 0.19 (0–0.56)
Charlson comorbidity Index
0 (%) 15 (15.6)
1 (%) 28 (29.2)
≥2 (%) 53 (55.2)
Abbreviations: %M, percent males; BMI, body mass index; no., numbers; ICS, 
inhaled corticosteroids; FEV1, forced expiratory volume in 1st second; pred., pre-
dicted; conc., concentration; exa, exacerbations.
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Subgroup Analyses
As FEV1 is known to be associated with sex, we 
performed separate subgroup analyses for men and 
women.
Among the 51 patients who resumed ICS during the 
6 months follow-up, 20 patients (39.2%) were men. 
They experienced a statistically significant decline in 
FEV1 of 0.153 liters, p < 0.05, as well as a non-sig-
nificant decline in blood eosinophils (Δ0.08 x10E9/L). 
On the opposite, the 31 women (60.8%) did not experi-
ence any change in FEV1 from baseline to 6 months 
follow-up (ΔFEV1 −0.011 liters, p = 0.72), whereas we 
measured a non-significant increase in blood eosinophils 
from baseline to 3 months follow-up (Δblood eosino-
phils 0.03, p = 0.53).
Among the remaining 34 patients without ICS after 6 
months from withdrawal, 16 patients (47.1%) were men. 
They experienced a small non-significant decrease in 
FEV1 of 0.086 liters (p = 0.27) but no difference in 
blood eosinophils from baseline to 3 months of follow- 
up (Δblood eosinophils 0.005, p = 0.82). The 18 women 
(52.9%) had no change in FEV1 from baseline to 6 
months of follow-up (ΔFEV1 0.0039, p=0.92), however, 
we found a statistically significant increase in blood 
eosinophils from 0.15 x10E9/L to 0.23 x10E9/L, 
p<0.05.
Furthermore, we performed subgroup analyses for the 
seven patients who died during follow-up. Overall, com-
pared to patients alive at end of follow-up, these patients 
had more severe COPD with six patients classified as hav-
ing COPD GOLD D with a mean lung function at 0.68 liters 
(range 0.25–1.19 liters). In line with this, five patients had 
had exacerbations prior to inclusion. However, only one 
patient had resumed treatment with ICS after one month 
and another patient after 3 months (Suppl. Table 2).
Discussion
This study aimed to evaluate whether patients with 
COPD receiving triple therapy with a LAMA, a 
LABA and ICS could manage to stay off ICS after 
abrupt withdrawal. Eighty-five patients were included 
of whom 51 (60%) resumed treatment with ICS during 
follow-up. No differences regarding age, gender, smok-
ing status, lung function or number of exacerbations 
prior to inclusion were found between patients resum-
ing treatment with ICS and those not resuming 
treatment.
During follow-up, no significant change in lung 
function was seen between the two groups; however, a 
tendency of worsening of lung function was seen for 
patients resuming ICS (ΔFEV1 −0.07 L) whereas 
patients without ICS experienced a slight increase in 
lung function (ΔFEV1 0.04 L). Thirty-four patients 
(68%) resuming ICS experienced an exacerbation com-
pared to 15 patients (44%) not resuming ICS (p = 
0.039). This difference in exacerbations could be mis-
interpreted as a consequence of treatment with ICS, 
however, ICS treatment was most likely resumed fol-
lowing an exacerbation. Another, more likely, explana-
tion for this finding could be that patients who did not 
manage to stay off ICS were more susceptible to varia-
tions in symptoms and felt more comfortable when 
treated with ICS and consequently had a lower threshold 
for exacerbations.
No differences from baseline in lung function, eosino-
philic count or number of exacerbations prior to inclusion 
were reported between the two groups and could therefore 
not explain why some patients managed to stay off ICS 
during follow-up.
In recent years, it has become evident that not all 
patients with COPD will benefit from ICS therapy, 
Table 2 Exacerbations, Use of Antibiotics and FEV1 During Follow-Up













No of pts with exacerbations 23 6 19 7 22 9
No of pts treated with antibiotics 20 6 11 3 16 8
FEV1 L (%), mean 0.96 (41) 1.00 (41) 0.97 (41) 0.97 (40) 0.91 (39) 0.96 (39)
Abbreviations: FEV1, forced expiratory volume in 1st second; + ICS, resumed inhaled corticosteroids; - ICS, withdrawal from inhaled corticosteroids; no, numbers; pts, 
patients.
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particularly if they are maintained on effective dual 
bronchodilation with a LABA and LAMA.14 It is neces-
sary to identify on a case-by-case basis who will benefit 
from ICS therapy, and if a patient is already treated with 
ICS whether it will be beneficial to step down or even 
stop ICS treatment without doing harm. Several pre-
vious studies have shown that abrupt withdrawal of 
ICS was associated with an increased risk of exacerba-
tions and worsening of lung function12,16,20 resulting in 
studies proposing stepwise ICS withdrawal.21–23 Despite 
of this, we have chosen abrupt withdrawal of ICS to 
make the study doable, as more patients were 
expected to drop out during a prolonged stepwise 
discontinuation. Furthermore, abrupt withdrawal is 
more feasible in a real-life clinical setting making this 
study applicable to most outpatient clinics. In our study, 
we did not find an overall increased risk of exacerba-
tions or worsening of lung function after abrupt with-
drawal of ICS. This is in line with a previous study 
(SUNSET) from 2018 evaluating the efficacy and safety 
of direct de-escalation from long-term triple therapy in 
non-frequently exacerbating patients with COPD.24 
However, only 34 of 85 patients in our study managed 
to stay off ICS during follow-up. In the SUNSET study, 
it was shown that patients with ≥300 blood eosinophils/ 
µL had a higher risk of exacerbation after ICS with-
drawal indicating that these patients benefit from ICS in 
combination with LAMA/LABA.24 In our study, we 
were not able to show this regarding risk of exacerba-
tions. However, we did find a tendency towards higher 
blood eosinophils in the group of patients who resumed 
ICS during follow-up.
One of the major strengths of this study is that data 
is collected in real-time which reflects patients’ ability 
to withdraw ICS as they could at any time resume 
treatment with ICS. To our knowledge, this is the first 
study to evaluate the ability to accept abrupt withdrawal 
of ICS in patients treated with ICS for a long time. 
Another strength is that measurement of lung function 
was performed by the same staff at every visit and in 
the same setting resulting in an overall high quality of 
spirometries.
The study has some limitations as well. The most 
important one might be that patients were not asked 
why they needed to resume treatment with ICS. 
Information of possible worsening of dyspnea, sputum 
production, quality of life and anxiety would have been 
useful as predictors of resuming ICS. With this infor-
mation, it could have been possible in future settings to 
inform patients about situations and adverse effects 
which could give rise to a need for resuming ICS and 
thereby prepare the patients better for this. In line with 
this, we do not have data on the initial indications for 
treatment with ICS. However, a study from 2010 
Table 3 Baseline Characteristics Among the 2 Groups
Total Population Concluding the Study (n = 85)





Gender (%M) 16 (47.1) 20 (40.0) 0.53
BMI, mean (range) 25.7 (17–38) 24.7 (12–44)
Age – years, mean (±) 69.9 (51–86 yrs) 70.5 (52–94 yrs) 0.64
GOLD (%)
A 2 (5.9) 2 (3.9)
B 10 (29.4) 9 (17.6)
C 2 (5.9) 6 (11.8)
D 20 (58.8) 34 (66.7)
MRC (%)
1 1 (2.9%) 1 (2%)
2 10 (29.4%) 8 (15.7%)
3 12 (35.3%) 19 (37.3%)
4 7 (20.6%) 16 (31.4%)
5 4 (11.8%) 7 (13.7%)
Smoking history
Former smokers (%) 24 (70.6) 42 (82.4) 0.14
Current smokers (%) 10 (29.4) 9 (17.6) 0.22
Pack years, mean 45.24 44.74




FEV1 liters 1.00 0.96 0.63




No. of patients with 
exacerbations prior 
to inclusion (%)
18 (53) 27 (54) 0.93
Charlson 
comorbidity Index
0 (%) 5 (14.7) 9 (17.6) 0.72
1 (%) 9 (26.5) 16 (31.4) 0.63
≥2 (%) 20 (58.8) 26 (51.0) 0.48
Abbreviations: ICS, inhaled corticosteroids; %M, percent males; BMI, body mass 
index; n, numbers; FEV1, forced expiratory volume in 1st second; conc., concentra-
tion; no., numbers.
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conducted in Denmark showed that 75% of 
patients diagnosed with COPD were started on ICS 
by their General Practitioner indicating that this was 
the treatment of choice some years ago.15 Another 
limitation is that only patients with a known history 
of asthma are excluded. We have not performed spiro-
metry with reversibility prior to inclusion as this would 
have required patients to pause their inhalation 
treatment for up to 4 weeks prior to spirometry 
which we did not find ethically correct. Patients resum-
ing ICS could therefore theoretically have a 
co-diagnosis of asthma explaining their need for ICS 
in everyday life without our knowledge. However, we 
find this very unlikely as patients were all known 
with a diagnosis of COPD, had a mean age of 70 
years and were all former or current smokers. Finally, 
with 91 patients included, the study might have been 
underpowered. With a greater sample size, some of the 
observed differences in eosinophilic count at 
baseline and number of exacerbations during follow- 
up might have been statistically significant.
In conclusion, abrupt withdrawal of ICS was possible 
in some patients. However, more than half of the patients 
resumed ICS during follow-up. No differences in lung 
function were seen between the two groups during fol-
low-up as well as no differences from baseline in lung 
function, eosinophilic count or number of exacerbations 
prior to inclusion were reported between the two groups. 
However, significantly more patients who resumed treat-
ment with ICS experienced one or more exacerbations 
during follow-up.
Figure 2 Exacerbations according to treatment. Numbers in parentheses indicate percentages. 
Abbreviation: ICS, inhaled corticosteroids.









Up (n = 51)
p-value
No. of patients 
with 
exacerbations (%)
15 (44.1%) 34 (68%) 0.09
ΔFEV1 0.04 L −0.07 L 0.55
Abbreviations: ICS, inhaled corticosteroids; n, numbers; no., numbers; FEV1, 
forced expiratory volume in 1st second.
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Based on results from this study we were not able to 
foresee who will be able to manage without ICS and who 
will resume treatment with ICS.
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Table 5 EOS According to Phenotype and Use of ICS






EOS at baseline 0.24 0.28 0.61
EOS at 3 months 0.25 0.21 0.49





EOS at baseline 0.15 0.18 0.44
EOS at 3 months 0.17 0.24 0.23





EOS at baseline 0.24 0.15 0.15
EOS at 3 months 0.25 0.17 0.14





EOS at baseline 0.28 0.18 0.21
EOS at 3 months 0.21 0.24 0.66
Abbreviations: EOS, blood eosinophil count; ICS, inhaled corticosteroids; n, 
numbers.
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